"Klinische Studien sind der Schlüssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen."

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

In der Schweiz zugelassene First-in-Class-Medikamente seit 2000

(Stand Juni. 2018)

25

Durchschnittliche Anzahl klinische Studien in der Schweiz pro Jahr

(Stand Juni. 2018)

70

Millionen Schweizer Franken in die Forschung investiert, seit 2012

(Stand Juni. 2018)

Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung im Citybay in Luzern koordiniert.
Unsere Niederlassungen

Das klinische Studienprogramm von MSD in der Schweiz ist breit gefächert (Stand Juni. 2018)

Laufende klinische Studien von MSD in der Schweiz

Studie

Studiencenter

MK-3475 Prot. 002: MK-3475 versus Chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma (P08719)

Zürich, Basel, Lausanne

MK-3475 Prot. 040: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Luzern, Bern, Genf

MK-3475 Prot. 042: A Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Bern, Freiburg, Basel

MK-3475 Prot. 048: A Phase III Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Lausanne, Zürich, Basel

MK-3475 Prot. 062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Lausanne, Bern, Zürich, Basel, Chur

MK-3475 Prot. 119: A Randomized, Open-Label, Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Bellinzona, Zürich, Bern

MK-3475 Prot. 170: A Phase II Study of Pembrolizumab (MK-3475) in subjects with Relapsed or Refractory Primary Mediastinal LaRKe B-cell Lypmhoma (rrPMBCL)

Bellinzona

MK-3475 Prot. 177: A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability - High or Mismatched Repair Deficient Stage IV Colon Rectal Carcinoma

Zürich, Basel

MK-3475 Prot. 199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy

Chur, St.Gallen, Luzern, Basel

MK-3475 Prot. 252: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination with Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma

Zürich, Lausanne, Genf

MK-3475 Prot. 495: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Zürich, St. Gallen, Chur, Basel, Genf

MK-3475 Prot. 587: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

Zürich

MK-3475 Prot. 604: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/ Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Zürich, Lausanne

MK-3475 Prot. 654: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Zürich, Bern, Genf, Bellinzona

MK-3475 Prot. 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Zürich, Genf, Bellinzona

MK-3475 Prot. 716: Indication: Melanoma - Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected Stage II Melanoma: A Randomized, Double-blind Phase III Study (KEYNOTE 716)

Zürich, St.Gallen, Lausanne, Bern, Bellinzona, Sion, Chur, Genf

MK-3475 Prot. 002: MK-3475 versus Chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma (P08719)

Zürich, Basel, Lausanne

MK-3475 Prot. 040: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Luzern, Bern, Genf

MK-3475 Prot. 042: A Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Bern, Freiburg, Basel

MK-3475 Prot. 048: A Phase III Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Lausanne, Zürich, Basel

MK-3475 Prot. 062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Lausanne, Bern, Zürich, Basel, Chur

MK-3475 Prot. 119: A Randomized, Open-Label, Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Bellinzona, Zürich, Bern

MK-3475 Prot. 170: A Phase II Study of Pembrolizumab (MK-3475) in subjects with Relapsed or Refractory Primary Mediastinal LaRKe B-cell Lypmhoma (rrPMBCL)

Bellinzona

MK-3475 Prot. 177: A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability - High or Mismatched Repair Deficient Stage IV Colon Rectal Carcinoma

Zürich, St.Gallen, Basel, Genf

MK-3475 Prot. 199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy

Chur, St.Gallen, Luzern, Basel

MK-3475 Prot. 252: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination with Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma

Zürich, Lausanne, Genf

MK-3475 Prot. 495: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Zürich, St. Gallen, Chur, Basel, Genf

MK-3475 Prot. 587: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

Zürich

MK-3475 Prot. 604: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/ Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Zürich, Lausanne

MK-3475 Prot. 654: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Zürich, Bern, Genf, Bellinzona

MK-3475 Prot. 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Zürich, Genf, Bellinzona

MK-3475 Prot. 716: Indication: Melanoma - Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected Stage II Melanoma: A Randomized, Double-blind Phase III Study (KEYNOTE 716)

Zürich, St.Gallen, Lausanne, Bern, Bellinzona, Sion, Chur, Genf

Studie

MK-1242 Prot. 001: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Studiencenter

Lausanne, Bellinzona, Basel

MK-1242 Prot. 001: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Lausanne, Bellinzona, Basel

Studie

Studiencenter

MK-5592 Prot. 069: Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosios in Adults and Adolescents (P06200)

Bern, Zürich, Basel

MK-5172 Prot. 017: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial.

Zürich

MK-1439A Prot. 021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naive HIV-1 Infected Subjects

Lausanne, Zürich, Genf

MK-1439A Prot. 024: A Phase III Mulitcenter, Open-label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Lausanne, Zürich, Bern

MK-5592 Prot. 069: Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosios in Adults and Adolescents (P06200)

Bern, Zürich, Basel

MK-5172 Prot. 017: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial.

Zürich

MK-1439A Prot. 021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naive HIV-1 Infected Subjects

Lausanne, Zürich, Genf

MK-1439A Prot. 024: A Phase III Mulitcenter, Open-label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Lausanne, Zürich, Bern

Zur Übersicht der schweizweiten Studien, die Teilnehmende suchen. www.kofam.ch